Infect Disord Drug Targets. 2018 Jun 28. doi: 10.2174/1871526518666180628122400. [Epub ahead of print]
Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications.
Hong B1, Wen Y1, Ying T1.
Author information
1
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032. China.
Abstract
BACKGROUND:
Hepatitis B virus (HBV) infection remains a global health problem. As "cure" for chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized for several decades to provide post-exposure prophylaxis. In recent years, a number of monoclonal antibodies (mAbs) targeting HBV have been developed and demonstrated with high affinity, specificity, and neutralizing potency.
OBJECTIVE:
HBV neutralizing antibodies may play potentially significant role in the search for an HBV cure. In this review, we will summarize the recently progress in developing HBV-neutralizing antibodies, describe their characteristics and potential clinical applications.
RESULTS AND CONCLUSION:
HBV neutralizing antibodies could be a promising alternative in the prevention and treatment of HBV infection. More importantly, global collaboration and coordinated approaches are thus needed to facilitate the development of novel therapies for HBV infection.